EUVIMEDOpdag EUVIMED
Open access

Targeting mitocytosis potentiates mitochondria drug delivery for antimetastasis therapy

Yudi Deng iD, Yunhui Zhang, Fuya Jia, Peihang Jiang iD, Lian Li iD, Yuan Huang iD

Science Advances · 2026

DOI: 10.1126/sciadv.aec7150 ↗

At a glance

Journal article in Science Advances, 2026. Written by Yudi Deng and 5 co-authors. Institution: Key Laboratory of Drug-Targeting and Drug Delivery System of the Education Ministry and Sichuan Province, Sichuan Engineering Laboratory for Plant-So…. Major MEDLINE topics: Mitochondria, Drug Delivery Systems, Antineoplastic Agents, Breast Neoplasms. Cited 2 times so far (Crossref); 25 references. The full text is freely available in PubMed Central. Funded by: National key R&D program of China, Regional Innovation and Development Joint Fund.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Mitocytosis is a compensatory pathway responding to mitochondria stress in migratory cells, which expels damaged mitochondria through migrasomes, preserving mitochondrial homeostasis and cellular viability. We found distinct responses to mitochondria-targeted therapy across breast tumor models distinguished by migrasome expression (4T1 > E0771 > EMT6). The antimetastatic efficacy of mitochondrial damage was notably compromised in the migrasome-high 4T1 tumor model due to robust mitocytosis activation, which is merely explored and lacks effective strategy. Here, we developed a mitochondria-targeted nanoplatform (RH-NPs) with the functions of mitocytosis inhibition and mitochondrial damage. Mitochondria-targeted triphenylphosphonium-modified lonidamine (TPP-LND) and integrin inhibitor cilengitide (CGT) were separately loaded into a nanodelivery system (TL/RH-NPs and CGT/RH-NPs, respectively). TL/RH-NPs effectively targeted and damaged tumor mitochondria. Simultaneously, upon mitocytosis activation, CGT/RH-NPs hitchhiked with damaged mitochondria into migrasomes to block mitocytosis via integrin inhibition. This strategy significantly potentiated antimetastatic efficacy in 4T1 tumor models, which established an effective approach for mitocytosis modulation and optimization of mitochondria-targeted therapies.

Subjects

MeSH terms (MEDLINE)

MitochondriaDrug Delivery SystemsAntineoplastic AgentsBreast NeoplasmsAnimalsMiceFemaleCell Line, TumorHumansNeoplasm MetastasisCell MovementNanoparticlesIndazoles

Substances

Antineoplastic AgentslonidamineIndazoles

Authors and institutions

  • Key Laboratory of Drug-Targeting and Drug Delivery System of the Education Ministry and Sichuan Province, Sichuan Engineering Laboratory for Plant-Sourced Drug and Sichuan Research Center for Drug Precision Industrial T…

ORCID profiles: Yudi Deng, Peihang Jiang, Lian Li, Yuan Huang

Funding

  • National key R&D program of China
  • Regional Innovation and Development Joint Fund

Cite

APA

Deng, Y., Zhang, Y., Jia, F., Jiang, P., Li, L., & Huang, Y. (2026). Targeting mitocytosis potentiates mitochondria drug delivery for antimetastasis therapy. Science Advances. https://doi.org/10.1126/sciadv.aec7150

Vancouver

Deng Y, Zhang Y, Jia F, Jiang P, Li L, Huang Y. Targeting mitocytosis potentiates mitochondria drug delivery for antimetastasis therapy. Science Advances. 2026. doi:10.1126/sciadv.aec7150

BibTeX
@article{Deng2026,
  author = {Deng, Yudi and Zhang, Yunhui and Jia, Fuya and Jiang, Peihang and Li, Lian and Huang, Yuan},
  title = {Targeting mitocytosis potentiates mitochondria drug delivery for antimetastasis therapy},
  journal = {Science Advances},
  year = {2026},
  doi = {10.1126/sciadv.aec7150}
}
Start for free →